Evidence map›Paper›PMID 40214496›Full record

ArticleCells2025

Targeted Control of Gene Expression Using CRISPR-Associated Endoribonucleases.

Sagar J Parikh, Heather M Terron, Luke A Burgard, Derek S Maranan, Dylan D Butler, Abigail Wiseman, Frank M LaFerla, Shelley Lane, Malcolm A Leissring

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sagar J ParikhInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Heather M TerronInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Luke A BurgardInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Derek S MarananInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Dylan D ButlerInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Abigail WisemanInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Frank M LaFerlaInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Shelley LaneInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.
Malcolm A LeissringInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697, USA.ORCID 0000-0001-7185-4255

Funding

Temporal and Spatial Aspects of Amyloidogenesis in Sporadic Alzheimer DiseaseR01AG066928 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI FRANK M LAFERLA · 2021 to 2026
$3.6M
NIA NIH HHS R01 AG066928NIH HHS 1R01AG066928-04A1
6 · The paper itself

Abstract

CRISPR-associated endoribonucleases (Cas RNases) cleave single-stranded RNA in a highly sequence-specific manner by recognizing and binding to short RNA sequences known as direct repeats (DRs). Here, we investigate the potential of exploiting Cas RNases for the regulation of target genes with one or more DRs introduced into the 3' untranslated region, an approach we refer to as DREDGE (direct repeat-enabled downregulation of gene expression). The DNase-dead version of Cas12a (dCas12a) was identified as the most efficient among five different Cas RNases tested and was subsequently evaluated in doxycycline-regulatable systems targeting either stably expressed fluorescent proteins or an endogenous gene. DREDGE performed superbly in stable cell lines, resulting in up to 90% downregulation with rapid onset, notably in a fully reversible and highly selective manner. Successful control of an endogenous gene with DREDGE was demonstrated in two formats, including one wherein both the DR and the transgene driving expression of dCas12a were introduced in one step by CRISPR-Cas. Our results establish DREDGE as an effective method for regulating gene expression in a targeted, highly selective, and fully reversible manner, with several advantages over existing technologies.

Indexed as

CRISPR-Associated ProteinsCRISPR-Cas SystemsEndoribonucleasesGene Expression RegulationGene EditingHEK293 CellsHumansCRISPR-Associated ProteinsEndoribonucleasesCRISPRdirect repeatendoribonucleasegene regulationRNA interference

Identifiers

PMID40214496
PMCPMC11988398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.